The technologies include SHetA2, a novel anti-HPV therapeutic candidate for the treatment of Cervical Intraepithelial Neoplasia (CIN), licensed to Emcure Pharmaceuticals Ltd., and two next-generation vaccine technologies against enteric bacterial infections, developed at ICMR–National Read More
